BMJ Open · 2019 · 89 citations · 33 references
MedicineEndocrinologyPediatricsPediatric Clinical PharmacologyPediatric EndocrinologyPediatric ImmunologyDiabetes ControlDiabetes ManagementDiabetes MellitusDiabetes PreventionInsulin TherapyDiabetes Management In ChildrenGenetic Risk ScreeningGenetic Risk StratificationHuman Leukocyte Antigen GenotypeImpaired Glucose ToleranceInfant Diabetes MellitusLong-term Diabetes PreventionPrimary Outcome Analysis
INTRODUCTION: The POInT study, an investigator initiated, randomised, placebo-controlled, double-blind, multicentre primary prevention trial is conducted to determine whether daily administration of oral insulin, from age 4.0 months to 7.0 months until age 36.0 months to children with elevated genetic risk for type 1 diabetes, reduces the incidence of beta-cell autoantibodies and diabetes. METHODS AND ANALYSIS: Infants aged 4.0 to 7.0 months from Germany, Poland, Belgium, UK and Sweden are eligible if they have a >10.0% expected risk for developing multiple beta-cell autoantibodies as determined by genetic risk score or family history and human leucocyte antigen genotype. Infants are randomised 1:1 to daily oral insulin (7.5 mg for 2 months, 22.5 mg for 2 months, 67.5 mg until age 36.0 months) or placebo, and followed for a maximum of 7 years. Treatment and follow-up is stopped if a child develops diabetes. The primary outcome is the development of persistent confirmed multiple beta-cell autoantibodies or diabetes. Other outcomes are: (1) Any persistent confirmed beta-cell autoantibody (glutamic acid decarboxylase (GADA), IA-2A, autoantibodies to insulin (IAA) and zinc transporter 8 or tetraspanin 7), or diabetes, (2) Persistent confirmed IAA, (3) Persistent confirmed GADA and (4) Abnormal glucose tolerance or diabetes. ETHICS AND DISSEMINATION: The study is approved by the ethical committees of all participating clinical sites. The results will be disseminated through peer-reviewed journals and conference presentations and will be openly shared after completion of the trial. TRIAL REGISTRATION NUMBER: NCT03364868.
33
A Multiple Testing Procedure for Clinical Trials
Peter C. O’Brien, Thomas R. Fleming · Biometrics · 1979 · 3.3K citations
Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy
George Du Toit, Graham Roberts, Peter H. Sayre et al. · New England Journal of Medicine · 2015 · 2.2K citations · Full text
Medicine, Child Health, Pediatrics +13
Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children
Anette G. Ziegler, Marian Rewers, Olli Simell et al. · JAMA · 2013 · 1.3K citations · Full text
Medicine, Endocrinology, Pediatrics +13
Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus
Petros Vafiadis, Simon T. Bennett, John A. Todd et al. · Nature Genetics · 1997 · 816 citations
Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
Diabetes Care · 2005 · 671 citations